Cargando…
Therapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy
SIMPLE SUMMARY: Multiple myeloma (MM) is the second most common haematological malignancy. Despite huge progress associated with the introduction of new antimyeloma drugs, MM remains an incurable disease. In this review, we discuss the role of the innate lymphoid system, its role in the pathogenesis...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507621/ https://www.ncbi.nlm.nih.gov/pubmed/34638291 http://dx.doi.org/10.3390/cancers13194806 |
_version_ | 1784581895680425984 |
---|---|
author | Szudy-Szczyrek, Aneta Ahern, Sean Kozioł, Magdalena Majowicz, Daria Szczyrek, Michał Krawczyk, Janusz Hus, Marek |
author_facet | Szudy-Szczyrek, Aneta Ahern, Sean Kozioł, Magdalena Majowicz, Daria Szczyrek, Michał Krawczyk, Janusz Hus, Marek |
author_sort | Szudy-Szczyrek, Aneta |
collection | PubMed |
description | SIMPLE SUMMARY: Multiple myeloma (MM) is the second most common haematological malignancy. Despite huge progress associated with the introduction of new antimyeloma drugs, MM remains an incurable disease. In this review, we discuss the role of the innate lymphoid system, its role in the pathogenesis of the disease, and the mechanisms by which innate lymphoid cells (ILC) can theoretically achieve therapeutic benefit in MM treatment. ABSTRACT: Innate lymphoid cells (ILCs) are a recently identified family of lymphocyte-like cells lacking a specific antigen receptor. They are part of the innate immune system. They play a key role in tissue homeostasis and also control inflammatory and neoplastic processes. In response to environmental stimuli, ILCs change their phenotype and functions, and influence the activity of other cells in the microenvironment. ILC dysfunction can lead to a wide variety of diseases, including cancer. ILC can be divided into three subgroups: ILC Group 1, comprising NK cells and ILC1; Group 2, including ILC2 alone; and Group 3, containing Lymphoid Tissue inducers (LTi) and ILC3 cells. While Group 1 ILCs mainly exert antitumour activity, Group 2 and Group 3 ILCs are protumorigenic in nature. A growing body of preclinical and clinical data support the role of ILCs in the pathogenesis of multiple myeloma (MM). Therefore, targeting ILCs may be of clinical benefit. In this manuscript, we review the available data on the role of ILCs in MM immunology and therapy. |
format | Online Article Text |
id | pubmed-8507621 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85076212021-10-13 Therapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy Szudy-Szczyrek, Aneta Ahern, Sean Kozioł, Magdalena Majowicz, Daria Szczyrek, Michał Krawczyk, Janusz Hus, Marek Cancers (Basel) Review SIMPLE SUMMARY: Multiple myeloma (MM) is the second most common haematological malignancy. Despite huge progress associated with the introduction of new antimyeloma drugs, MM remains an incurable disease. In this review, we discuss the role of the innate lymphoid system, its role in the pathogenesis of the disease, and the mechanisms by which innate lymphoid cells (ILC) can theoretically achieve therapeutic benefit in MM treatment. ABSTRACT: Innate lymphoid cells (ILCs) are a recently identified family of lymphocyte-like cells lacking a specific antigen receptor. They are part of the innate immune system. They play a key role in tissue homeostasis and also control inflammatory and neoplastic processes. In response to environmental stimuli, ILCs change their phenotype and functions, and influence the activity of other cells in the microenvironment. ILC dysfunction can lead to a wide variety of diseases, including cancer. ILC can be divided into three subgroups: ILC Group 1, comprising NK cells and ILC1; Group 2, including ILC2 alone; and Group 3, containing Lymphoid Tissue inducers (LTi) and ILC3 cells. While Group 1 ILCs mainly exert antitumour activity, Group 2 and Group 3 ILCs are protumorigenic in nature. A growing body of preclinical and clinical data support the role of ILCs in the pathogenesis of multiple myeloma (MM). Therefore, targeting ILCs may be of clinical benefit. In this manuscript, we review the available data on the role of ILCs in MM immunology and therapy. MDPI 2021-09-26 /pmc/articles/PMC8507621/ /pubmed/34638291 http://dx.doi.org/10.3390/cancers13194806 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Szudy-Szczyrek, Aneta Ahern, Sean Kozioł, Magdalena Majowicz, Daria Szczyrek, Michał Krawczyk, Janusz Hus, Marek Therapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy |
title | Therapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy |
title_full | Therapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy |
title_fullStr | Therapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy |
title_full_unstemmed | Therapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy |
title_short | Therapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy |
title_sort | therapeutic potential of innate lymphoid cells for multiple myeloma therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507621/ https://www.ncbi.nlm.nih.gov/pubmed/34638291 http://dx.doi.org/10.3390/cancers13194806 |
work_keys_str_mv | AT szudyszczyrekaneta therapeuticpotentialofinnatelymphoidcellsformultiplemyelomatherapy AT ahernsean therapeuticpotentialofinnatelymphoidcellsformultiplemyelomatherapy AT koziołmagdalena therapeuticpotentialofinnatelymphoidcellsformultiplemyelomatherapy AT majowiczdaria therapeuticpotentialofinnatelymphoidcellsformultiplemyelomatherapy AT szczyrekmichał therapeuticpotentialofinnatelymphoidcellsformultiplemyelomatherapy AT krawczykjanusz therapeuticpotentialofinnatelymphoidcellsformultiplemyelomatherapy AT husmarek therapeuticpotentialofinnatelymphoidcellsformultiplemyelomatherapy |